A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients

British Journal of Clinical Pharmacology

Volumn 62, Issue 4, 2006, Pages 477-484

  Picard, Nicolas ^a   Prémaud, Aurélie ^b   Rousseau, Annick ^b   Le Meur, Yannick ^b   Marquet, Pierre ^a,b  

^a UNIVERSITY OF LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Kidney transplantation; Metabolism; Mycophenolate mofetil; Sirolimus

Indexed keywords

CYCLOSPORIN; DRUG METABOLITE; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID ACYLGLUCURONIDE; MYCOPHENOLIC ACID PHENYLGLUCOSIDE; MYCOPHENOLIC ACID PHENYLGLUCURONIDE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG METABOLISM; FEMALE; GLYCOSYLATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER MICROSOME; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADULT; AGED; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 33748746020     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02509.x     Document Type: Article

References (28)

1. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-6.
2. Pillans PI, Rigby RJ, Kubler P, Willis C, Salm P, Tett SE, Taylor PJ. A retrospective analysis of mycophenolic acid and ciclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 2001; 34: 77-81.
3. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079-83.
4. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-15.
5. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G, Voihsel M, Braun F, Oellerich M. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126: 1075-82.
6. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-55.
7. Shipkova M, Wieland E, Schutz E, Wiese C, Niedmann PD, Oellerich M, Armstrong VW. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001; 33: 1080-1.
8. Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann PD, Armstrong VW, Oellerich M. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000; 33: 107-13.
9. Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25: 609-22.
10. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225-32.
11. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999; 21: 536-9.
12. Smak Gregoor P, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without ciclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14: 706-8.
13. Kobayashi M, Saitoh H, Tadano K, Takahashi Y, Hirano T. Ciclosporin A but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004; 309: 1029-35.
14. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999; 21: 35-43.
15. Vietri M, Pietrabissa A, Mosca F, Pacifici GM. Mycophenolic acid glucuronidation and its inhibition by non-steroidal antiinflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 2000; 56: 659-64.
16. Balogh A, Merkel U, Muller D. Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices? Exp Toxicol Pathol 2003; 54: 375-9.
17. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with ciclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-42.
18. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus ciclosporine. Transplantation 2002; 74: 1070-6.
19. Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001; 23: 559-86.
20. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000; 46: 365-72.
21. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-32.
22. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the udp-glucuronosyltransferase isoforms involved in mycophenolic Acid phase II metabolism. Drug Metab Dispos 2005; 33: 139-46.
23. Vietri M, Pietrabissa A, Mosca F, Pacifici GM. Inhibition of mycophenolic acid glucuronidation by niflumic acid in human liver microsomes. Eur J Clin Pharmacol 2002; 58: 93-7.
24. Premaud A, Rousseau A, Le Meur Y, Lachatre G, Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004; 26: 609-19.
25. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 2001; 52: 605-9.
26. Shipkova M, Strassburg CP, Braun F, Streit F, Grone HJ, Armstrong VW, Tukey RH, Oellerich M, Wieland E. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001; 132: 1027-34.
27. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003; 25: 1-16.
28. Innocenti F, Undevia SD, Ramirez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacologic modulation of irinotecan with ciclosporine and phenobarbital. Clin Pharmacol Ther 2004; 76: 490-502.